A Systematic Review of the Prognostic Value of Cardiopulmonary Exercise Testing in Patients with Ischemic and Nonischemic Cardiomyopathy

心肺运动试验对缺血性和非缺血性心肌病患者预后价值的系统评价

阅读:2

Abstract

BACKGROUND: The prognostic utility of cardiopulmonary exercise testing (CPET) in heart failure (HF) is well established; however, whether optimal CPET parameter thresholds differ across HF etiologies remains unclear. This systematic review aimed to determine how CPET-derived parameters and their prognostic threshold values differ, and their association with adverse outcomes, in patients with ischemic vs nonischemic cardiomyopathy. METHODS: Eligible studies assessed adult HF patients and reported outcomes of all-cause mortality, left ventricular assist device implantation, heart transplantation, or hospitalization. CPET parameters and associated threshold values were extracted, and risk of bias was assessed using the Joanna Briggs Institute checklist for cohort studies. RESULTS: Four studies comprising 491 ischemic and 218 nonischemic HF patients were included. Peak oxygen consumption (pVO(2)) was the only CPET parameter unanimously reported. In ischemic HF, the optimal pVO(2) thresholds, in mL/kg/min, were ≤ 14.10 (hazard ratio [HR] 3.3; confidence interval [CI]: 1.9-5.8), ≤ 10.0 (HR 0.76; CI: 0.59-0.98), ≤ 15.20, and ≤ 14.0 (used in one study as a guideline comparator), yielding a mean threshold of ≤ 13.33 mL/kg/min ( ± 2.28). In nonischemic HF, optimal thresholds in mL/kg/min were ≤ 14.60 (HR 4.30 [CI: 2.10-8.90]) and ≤ 14.0, yielding a mean of ≤ 14.30 mL/kg/min ( ± 0.42). CONCLUSIONS: Significant heterogeneity was present in study design, patient populations, and CPET variables assessed. The few consistently assessed prognostic thresholds were similar across HF etiologies. Peak oxygen consumption (pVO(2)) remains a robust prognostic marker in both ischemic and nonischemic cardiomyopathy. Although patients with ischemic cardiomyopathy generally have worse clinical profiles, this review suggests that no meaningful differences occur in a few key CPET prognostic thresholds, namely pVO(2), across etiologies. These findings support continued use of established guideline-recommended thresholds for risk stratification, irrespective of HF subtype, but require further confirmation.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。